Recent advances in cancer vaccines: an overview (Q34882348)

5 August 2017

1 reference

title

Recent advances in cancer vaccines: an overview (English)

1 reference

5 August 2017

Kyogo Itoh

1

1 reference

5 August 2017

Akira Yamada

series ordinal

2

1 reference

5 August 2017

Takashi Mine

series ordinal

3

1 reference

5 August 2017

Masanori Noguchi

series ordinal

4

1 reference

5 August 2017

publication date

16 November 2008

1 reference

Japanese Journal of Clinical Oncology

5 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

5 August 2017

volume

39

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

73-80

1 reference

Hepatocellular carcinoma: an epidemiologic view

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Current developments in cancer vaccines and cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Therapeutic vaccines for melanoma: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN132

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYN132

1 reference

release_pzgxdiqksraebn7wvq6qn6z76e

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pzgxdiqksraebn7wvq6qn6z76e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference